These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 29958062)

  • 21. Assessment of Structural and Functional Comparability of Biosimilar Products: Trastuzumab as a Case Study.
    Joshi S; Rathore AS
    BioDrugs; 2020 Apr; 34(2):209-223. PubMed ID: 31975160
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate.
    Chen L; Wang L; Shion H; Yu C; Yu YQ; Zhu L; Li M; Chen W; Gao K
    MAbs; 2016 Oct; 8(7):1210-1223. PubMed ID: 27380163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tracking the Behavior of Monoclonal Antibody Product Quality Attributes Using a Multi-Attribute Method Workflow.
    Jakes C; Millán-Martín S; Carillo S; Scheffler K; Zaborowska I; Bones J
    J Am Soc Mass Spectrom; 2021 Aug; 32(8):1998-2012. PubMed ID: 33513021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies.
    Ishii-Watabe A; Kuwabara T
    Drug Metab Pharmacokinet; 2019 Feb; 34(1):64-70. PubMed ID: 30600193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery and characterization of antibody variants using mass spectrometry-based comparative analysis for biosimilar candidates of monoclonal antibody drugs.
    Li W; Yang B; Zhou D; Xu J; Ke Z; Suen WC
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jul; 1025():57-67. PubMed ID: 27214604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of an LC-MS/MS peptide mapping protocol for the NISTmAb.
    Mouchahoir T; Schiel JE
    Anal Bioanal Chem; 2018 Mar; 410(8):2111-2126. PubMed ID: 29411091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biosimilar infliximab: an expert view.
    Genazzani A; Altomare G; Balato N; Cusano F; De Pità O; Loconsole F; Micali G; Piaserico S; Girolomoni G
    G Ital Dermatol Venereol; 2015 Aug; 150(4):449-59. PubMed ID: 25747260
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determining Spectroscopic Quantitation Limits for Misfolded Structures.
    Kendrick BS; Gabrielson JP; Solsberg CW; Ma E; Wang L
    J Pharm Sci; 2020 Jan; 109(1):933-936. PubMed ID: 31521643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NMR based quality evaluation of mAb therapeutics: A proof of concept higher order structure biosimilarity assessment of trastuzumab biosimilars.
    Joshi S; Khatri LR; Kumar A; Rathore AS
    J Pharm Biomed Anal; 2022 May; 214():114710. PubMed ID: 35290923
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quality and Batch-to-Batch Consistency of Original and Biosimilar Epoetin Products.
    Halim LA; Brinks V; Jiskoot W; Romeijn S; Haselberg R; Burns C; Wadhwa M; Schellekens H
    J Pharm Sci; 2016 Feb; 105(2):542-550. PubMed ID: 26869417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification and characterization of monoclonal antibody fragments cleaved at the complementarity determining region using orthogonal analytical methods.
    Li W; Yang B; Zhou D; Xu J; Li W; Suen WC
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Mar; 1048():121-129. PubMed ID: 28242491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics.
    Sörgel F; Schwebig A; Holzmann J; Prasch S; Singh P; Kinzig M
    BioDrugs; 2015 Apr; 29(2):123-31. PubMed ID: 25837839
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification and characterization of carbonylation sites in trastuzumab biosimilars.
    Joshi S; Kumari S; Rathore AS
    Int J Biol Macromol; 2021 Feb; 169():95-102. PubMed ID: 33338527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Usability of NISTmAb reference material for biosimilar analytical development.
    Nupur N; Rathore AS
    Anal Bioanal Chem; 2019 May; 411(13):2867-2883. PubMed ID: 30859268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Considerations of critical quality attributes in the analytical comparability assessment of biosimilar products.
    Kwon O; Joung J; Park Y; Kim CW; Hong SH
    Biologicals; 2017 Jul; 48():101-108. PubMed ID: 28495312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of Excipient Extraction and Buffer Exchange on Recombinant Monoclonal Antibody Stability.
    Sarin D; Krishna K; Nejadnik MR; Suryanarayanan R; Rathore AS
    Mol Pharm; 2024 Apr; 21(4):1872-1883. PubMed ID: 38422397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modeling study of long-term stability of the monoclonal antibody infliximab and biosimilars using liquid-chromatography-tandem mass spectrometry and size-exclusion chromatography-multi-angle light scattering.
    Legrand P; Dufaÿ S; Mignet N; Houzé P; Gahoual R
    Anal Bioanal Chem; 2023 Jan; 415(1):179-192. PubMed ID: 36449030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Qualification of a LC-HRMS platform method for biosimilar development using NISTmab as a model.
    Tank P; Vora S; Tripathi S; D'Souza F
    Anal Biochem; 2024 May; 688():115475. PubMed ID: 38336012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enabling adoption of 2D-NMR for the higher order structure assessment of monoclonal antibody therapeutics.
    Brinson RG; Marino JP; Delaglio F; Arbogast LW; Evans RM; Kearsley A; Gingras G; Ghasriani H; Aubin Y; Pierens GK; Jia X; Mobli M; Grant HG; Keizer DW; Schweimer K; Ståhle J; Widmalm G; Zartler ER; Lawrence CW; Reardon PN; Cort JR; Xu P; Ni F; Yanaka S; Kato K; Parnham SR; Tsao D; Blomgren A; Rundlöf T; Trieloff N; Schmieder P; Ross A; Skidmore K; Chen K; Keire D; Freedberg DI; Suter-Stahel T; Wider G; Ilc G; Plavec J; Bradley SA; Baldisseri DM; Sforça ML; Zeri ACM; Wei JY; Szabo CM; Amezcua CA; Jordan JB; Wikström M
    MAbs; 2019 Jan; 11(1):94-105. PubMed ID: 30570405
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differentiating biosimilarity and comparability in biotherapeutics.
    Azevedo V; Hassett B; Fonseca JE; Atsumi T; Coindreau J; Jacobs I; Mahgoub E; O'Brien J; Singh E; Vicik S; Fitzpatrick B
    Clin Rheumatol; 2016 Dec; 35(12):2877-2886. PubMed ID: 27734233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.